Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Acquires $418,673.91 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc bought 17,763 shares of the stock in a transaction that occurred on Wednesday, February 11th. The shares were purchased at an average price of $23.57 per share, for a total transaction of $418,673.91. Following the completion of the acquisition, the insider owned 650,567 shares of the company’s stock, valued at $15,333,864.19. The trade was a 2.81% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc acquired 1,093 shares of Surrozen stock. The stock was purchased at an average cost of $23.86 per share, with a total value of $26,078.98.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The shares were purchased at an average price of $21.94 per share, for a total transaction of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc bought 731 shares of Surrozen stock. The stock was purchased at an average cost of $21.38 per share, for a total transaction of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc bought 4,271 shares of Surrozen stock. The stock was purchased at an average price of $21.39 per share, with a total value of $91,356.69.

Surrozen Stock Performance

Surrozen stock opened at $24.48 on Monday. The stock has a 50-day simple moving average of $21.59 and a 200 day simple moving average of $15.84. The stock has a market capitalization of $209.79 million, a P/E ratio of -1.10 and a beta of 0.58. Surrozen, Inc. has a 52 week low of $5.90 and a 52 week high of $25.84.

Institutional Trading of Surrozen

Several institutional investors have recently added to or reduced their stakes in SRZN. Braidwell LP acquired a new position in shares of Surrozen in the second quarter valued at about $1,252,000. Stempoint Capital LP boosted its holdings in Surrozen by 185.1% in the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after purchasing an additional 445,713 shares during the period. Stonepine Capital Management LLC grew its position in shares of Surrozen by 7.1% during the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Surrozen by 21.7% during the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after purchasing an additional 47,468 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Surrozen during the fourth quarter worth approximately $247,000. 66.57% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on SRZN shares. Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a report on Thursday, January 22nd. Finally, Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.